Valencia K, Luis-Ravelo D, Bovy N, Anton I, Martinez-Canarias S, Zandueta C, Ormazabal C, Struman I, Tabruyn S, Rebmann V, et al. (2014) miRNA cargo within exosome-like vesicle transfer influences metastatic bone colonization. Mol Oncol, 8; 689-703.


Rebmann V, da Silva Nardi F, Wagner B, Horn PA. (2014) HLA-G as a tolerogenic molecule in transplantation and pregnancy. J Immunol Res, 2014; 297073.


Kordelas L, Rebmann V, Ludwig AK, Radtke S, Ruesing J, Doeppner TR, Epple M, Horn PA, Beelen DW, Giebel B. (2014) MSC-derived exosomes: a novel tool to treat therapy-refractory graft-versus-host disease. Leukemia, 28; 970-973.




Pajtler KW, Rebmann V, Lindemann M, Schulte JH, Schulte S, Stauder M, Leuschner I, Schmid KW, Kohl U, Schramm A, Eggert A (2013) Expression of NTRK1/TrkA affects immunogenicity of neuroblastoma cells. Int J Cancer, 133; 908-919.


Martelli-Palomino G, Pancotto JA, Muniz YC, Mendes-Junior CT, Castelli EC, Massaro JD, Krawice-Radanne I, Poras I, Rebmann V, Carosella ED, et al. (2013) Polymorphic sites at the 3' untranslated region of the HLA-G gene are associated with differential hla-g soluble levels in the Brazilian and French population. PLoS One, 8;e71742.


Alegre E, Rebmann V, LeMaoult J, Rodriguez C, Horn PA, Diaz-Lagares A, Echeveste JI, Gonzalez A (2013) In vivo identification of an HLA-G complex as ubiquitinated protein circulating in exosomes. Eur J Immunol, 43; 1933-1939.



Nückel H, Castelli EC, Moreau P, Ochsenfarth C, Horn PA, and Rebmann V. (2012) Simple
methods for the detection of HLA-G variants in coding and non-coding regions.
Methods Mol Biol., 882; 123-42.


Iacob S, Cicinnati VR, Dechêne A, Lindemann M, Heinemann FM, Rebmann V,
Ferencik S, Sotiropoulos GC, Popescu I, Horn PA, Gerken G, Paul A, and Beckebaum S. (2012)
Genetic, immunological and clinical risk factors for biliary strictures following
liver transplantation. Liver Int. , 32, 1253-61.


González A, Rebmann V, LeMaoult J, Horn PA, Carosella ED, and Alegre E. (2012) The
immunosuppressive molecule HLA-G and its clinical implications. Crit Rev Clin Lab
Sci.;  49, 63-84.


Verloes, A., Van de Velde, H., LeMaoult, J., Mateizel, I., Cauffman, G., Horn, P. A., Carosella, E. D., Devroey, P., De Waele, M., Rebmann, V. et al. (2011) HLA-G expression in human embryonic stem cells and preimplantation embryos. J Immunol, 186, 2663-2671.

Rizzo, R., Vercammen, M., van de Velde, H., Horn, P. A. and Rebmann, V. (2011) The importance of HLA-G expression in embryos, trophoblast cells, and embryonic stem cells. Cell Mol Life Sci, 68, 341-352.


Schütt, P., Schütt, B., Switala, M., Bauer, S., Stamatis, G., Opalka, B., Eberhardt, W., Schuler, M., Horn, P. A. and Rebmann, V. (2010) Prognostic relevance of soluble human leukocyte antigen-G and total human leukocyte antigen class I molecules in lung cancer patients. Hum Immunol, 71, 489-495.

Rebmann, V., Switala, M., Eue, I. and Grosse-Wilde, H. (2010) Soluble HLA-G is an independent factor for the prediction of pregnancy outcome after ART: a German multi-centre study. Hum Reprod, 25, 1691-1698.

Nückel, H., Switala, M., Sellmann, L., Horn, P. A., Dürig, J., Dührsen, U., Küppers, R., Grosse-Wilde, H. and Rebmann, V. (2010) The prognostic significance of soluble NKG2D ligands in B-cell chronic lymphocytic leukemia. Leukemia, 24, 1152-1159.


Rebmann, V., Bartsch, D., Wunsch, A., Möllenbeck, P., Golda, T., Viebahn, R. and Grosse-Wilde, H. (2009) Soluble total human leukocyte antigen class I and human leukocyte antigen-G molecules in kidney and kidney/pancreas transplantation. Hum Immunol, 70, 995-999.

Nückel, H., Switala, M., Collins, C. H., Sellmann, L., Grosse-Wilde, H., Dührsen, U. and Rebmann, V. (2009) High CD49d protein and mRNA expression predicts poor outcome in chronic lymphocytic leukemia. Clin Immunol, 131, 472-480.


Schütt, P., Rebmann, V., Brandhorst, D., Wiefelsputz, J., Ebeling, P., Opalka, B., Seeber, S., Nowrousian, M. R., Moritz, T. and Grosse-Wilde, H. (2008) The clinical significance of soluble human leukocyte antigen class-I, ICTP, and RANKL molecules in multiple myeloma patients. Hum Immunol, 69, 79-87.

Rebmann, V., Wagner, S. and Grosse-Wilde, H. (2007) HLA-G expression in malignant melanoma. Semin Cancer Biol, 17, 422-429.


Rebmann, V., Switala, M., Eue, I., Schwahn, E., Merzenich, M. and Grosse-Wilde, H. (2007) Rapid evaluation of soluble HLA-G levels in supernatants of in vitro fertilized embryos. Hum Immunol, 68, 251-258.

Rebmann, V., Schütt, P., Brandhorst, D., Opalka, B., Moritz, T., Nowrousian, M. R. and Grosse-Wilde, H. (2007) Soluble MICA as an independent prognostic factor for the overall survival and progression-free survival of multiple myeloma patients. Clin Immunol, 123, 114-120.

Rebmann, V., Nückel, H., Dührsen, U. and Grosse-Wilde, H. (2007) HLA-G in B-chronic lymphocytic leukaemia: clinical relevance and functional implications. Semin Cancer Biol, 17, 430-435.

Rebmann, V., LeMaoult, J., Rouas-Freiss, N., Carosella, E. D. and Grosse-Wilde, H. (2007) Quantification and identification of soluble HLA-G isoforms. Tissue Antigens, 69 Suppl 1, 143-149.

Heinemann, F. M., Roth, I., Rebmann, V., Arnold, M. L., Witzke, O., Wilde, B., Spriewald, B. M. and Grosse-Wilde, H. (2007) Immunoglobulin isotype-specific characterization of anti-human leukocyte antigen antibodies eluted from explanted renal allografts. Hum Immunol, 68, 500-506.

Heinemann, F. M., Rebmann, V., Witzke, O., Philipp, T., Broelsch, C. E. and Grosse-Wilde, H. (2007) Association of elevated pretransplant sCD30 levels with graft loss in 206 patients treated with modern immunosuppressive therapies after renal transplantation. Transplantation, 83, 706-711.


Verbrüggen, L. A., Rebmann, V., Demanet, C., De Cock, S. and Grosse-Wilde, H. (2006) Soluble HLA-G in rheumatoid arthritis. Hum Immunol, 67, 561-567.

Lindemann, M., Ottinger, H. D., Elmaagacli, A. H., Trenschel, R., Rebmann, V., Beelen, D. W. and Grosse-Wilde, H. (2006) Donor cell reaction to OKT3 as predictor of chronic graft-vs-host disease in hematopoietic stem cell recipients. Exp Hematol, 34, 1753-1758.

Heinemann, F. M., Roth, I., Rebmann, V., Arnold, M. L., Spriewald, B. M. and Grosse-Wilde, H. (2006) Characterization of anti-HLA antibodies eluted from explanted renal allografts. Clin Transpl, 371-378.


Rebmann, V., LeMaoult, J., Rouas-Freiss, N., Carosella, E. D. and Grosse-Wilde, H. (2005) Report of the Wet Workshop for Quantification of Soluble HLA-G in Essen, 2004. Hum Immunol, 66, 853-863.

Nückel, H., Rebmann, V., Dürig, J., Dührsen, U. and Grosse-Wilde, H. (2005) HLA-G expression is associated with an unfavorable outcome and immunodeficiency in chronic lymphocytic leukemia. Blood, 105, 1694-1698.

Berlit, P., Stueper, B., Fink, I., Rebmann, V., Hoyer, P., Kreuzfelder, E. and Grosse-Wilde, H. (2005) Behcet's disease is associated with increased concentrations of antibodies against phosphatidylserine and ribosomal phosphoproteins. Vasa, 34, 176-180.


Lindemann, M., Rebmann, V., Ottinger, H. D., Schmolke, K., Kreuzfelder, E. and Grosse-Wilde, H. (2004) rhG-CSF effect on mixed lymphocyte cultures and circulating soluble HLA antigen levels in volunteer stem cell donors. Exp Hematol, 32, 1103-1109.

Heiligenhaus, A., Rebmann, V., Neubert, A., Plewa, S., Ferencik, S., Vogeler, U., Steuhl, K. P. and Grosse-Wilde, H. (2004) Soluble HLA class I and HLA-DR plasma levels in patients with anterior uveitis. Tissue Antigens, 63, 369-375.


Zhou, J. H., Ferencik, S., Rebmann, V., Yang, D. L., Lu, M., Roggendorf, M. and Grosse-Wilde, H. (2003) Molecular genetic and biochemical analysis of woodchuck (Marmota monax) MHC class I polymorphism. Tissue Antigens, 61, 240-248.

Wang, X., Liang, B., Rebmann, V., Lu, J., Celis, E., Kageshita, T., Grosse-Wilde, H. and Ferrone, S. (2003) Specificity and functional characteristics of anti-HLA-A mAbs LGIII-147.4.1 and LGIII-220.6.2. Tissue Antigens, 62, 139-148.
Steinborn, A., Rebmann, V., Scharf, A., Sohn, C. and Grosse-Wilde, H. (2003) Soluble HLA-DR levels in the maternal circulation of normal and pathologic pregnancy. Am J Obstet Gynecol, 188, 473-479.

Steinborn, A., Rebmann, V., Scharf, A., Sohn, C. and Grosse-Wilde, H. (2003) Placental abruption is associated with decreased maternal plasma levels of soluble HLA-G. J Clin Immunol, 23, 307-314.

Singer, G., Rebmann, V., Chen, Y. C., Liu, H. T., Ali, S. Z., Reinsberg, J., McMaster, M. T., Pfeiffer, K., Chan, D. W., Wardelmann, E. et al. (2003) HLA-G is a potential tumor marker in malignant ascites. Clin Cancer Res, 9, 4460-4464.

Rebmann, V., Ronin-Walknowska, E., Sipak-Szmigiel, O., Miklaszewicz, A., Czajkowska, E. and Grosse-Wilde, H. (2003) Soluble HLA-DR and soluble CD95 ligand levels in pregnant women with antiphospholipid syndromes. Tissue Antigens, 62, 536-541.

Rebmann, V., Regel, J., Stolke, D. and Grosse-Wilde, H. (2003) Secretion of sHLA-G molecules in malignancies. Semin Cancer Biol, 13, 371-377.

Rebmann, V., Busemann, A., Lindemann, M. and Grosse-Wilde, H. (2003) Detection of HLA-G5 secreting cells. Hum Immunol, 64, 1017-1024.

Müller, A., Kreuzfelder, E., Nyadu, B., Lindemann, M., Rebmann, V., Majetschak, M., Obertacke, U., Schade, U. F., Nast-Kolb, D. and Grosse-Wilde, H. (2003) Human leukocyte antigen-DR expression in peripheral blood mononuclear cells from healthy donors influenced by the sera of injured patients prone to severe sepsis. Intensive Care Med, 29, 2285-2290.

Bukur, J., Rebmann, V., Grosse-Wilde, H., Luboldt, H., Ruebben, H., Drexler, I., Sutter, G., Huber, C. and Seliger, B. (2003) Functional role of human leukocyte antigen-G up-regulation in renal cell carcinoma. Cancer Res, 63, 4107-4111.

Anastassiou, G., Rebmann, V., Wagner, S., Bornfeld, N. and Grosse-Wilde, H. (2003) Expression of classic and nonclassic HLA class I antigens in uveal melanoma. Invest Ophthalmol Vis Sci, 44, 2016-2019.


Verbruggen, L. A., Versaen, H., Rebmann, V., Duquet, W., De Cock, S., Grosse-Wilde, H. and Demanet, C. (2002) Soluble HLA-DR levels in serum are associated with therapy and genetic factors in rheumatoid arthritis. Hum Immunol, 63, 758-764.

Solier, C., Aguerre-Girr, M., Lenfant, F., Campan, A., Berrebi, A., Rebmann, V., Grosse-Wilde, H. and Le Bouteiller, P. (2002) Secretion of pro-apoptotic intron 4-retaining soluble HLA-G1 by human villous trophoblast. Eur J Immunol, 32, 3576-3586.

Rebmann, V., Ugurel, S., Tilgen, W., Reinhold, U. and Grosse-Wilde, H. (2002) Soluble HLA-DR is a potent predictive indicator of disease progression in serum from early-stage melanoma patients. Int J Cancer, 100, 580-585.

Ottinger, H. D., Rebmann, V., Pfeiffer, K. A., Beelen, D. W., Kremens, B., Runde, V., Schaefer, U. W. and Grosse-Wilde, H. (2002) Positive serum crossmatch as predictor for graft failure in HLA-mismatched allogeneic blood stem cell transplantation. Transplantation, 73, 1280-1285.

Kuipers, J. G., Bialowons, A., Dollmann, P., Jendro, M. C., Wagener, N., Rebmann, V., Ikeda, M., Huang, F., Grosse-Wilde, H., Yu, D. T. et al. (2002) The genetically-engineered secretory B27/Q10 chimeric molecule inhibits HLA-B27 restricted alloreactive T-lymphocytes. Clin Exp Rheumatol, 20, 455-462.


Ugurel, S., Rebmann, V., Ferrone, S., Tilgen, W., Grosse-Wilde, H. and Reinhold, U. (2001) Soluble human leukocyte antigen--G serum level is elevated in melanoma patients and is further increased by interferon-alpha immunotherapy. Cancer, 92, 369-376.

Rebmann, V., van der Ven, K., Passler, M., Pfeiffer, K., Krebs, D. and Grosse-Wilde, H. (2001) Association of soluble HLA-G plasma levels with HLA-G alleles. Tissue Antigens, 57, 15-21.

Lewandrowski, K. U., Rebmann, V., Passler, M., Schollmeier, G., Ekkernkamp, A., Grosse-Wilde, H. and Tomford, W. W. (2001) Immune response to perforated and partially demineralized bone allografts. J Orthop Sci, 6, 545-555.

Elsner, H. A., Drabek, J., Rebmann, V., Ambruzova, Z., Grosse-Wilde, H. and Blasczyk, R. (2001) Non-expression of HLA-B*5111N is caused by an insertion into the cytosine island at exon 4 creating a frameshift stop codon. Tissue Antigens, 57, 369-372.

Wagner, S. N., Rebmann, V., Willers, C. P., Grosse-Wilde, H. and Goos, M. (2000) Expression analysis of classic and non-classic HLA molecules before interferon alfa-2b treatment of melanoma. Lancet, 356, 220-221.

Verbruggen, L. A., Dumarey, N., Van de Velde, H., Rebmann, V., Flament, J., Van Wayenberge, C., Grosse-Wilde, H. and Demanet, C. (2000) Soluble HLA-DR antigen levels in serum correlate with rheumatoid arthritis disease activity and the presence of disease-associated epitopes. Tissue Antigens, 56, 436-440.

Steinborn, A., Sohn, C., Rebmann, V. and Grosse-Wilde, H. (2000) Haemolysis, elevated liver enzymes, low platelet count (HELLP) syndrome associated with increased maternal serum levels of soluble HLA-DR antigens. Aust N Z J Med, 30, 511-512.

Poehlau, D., Kiltz, U., Rieks, M., Hoffmann, V., Rebmann, V., Schimrigk, S., Grosse-Wilde, H. and Przuntek, H. (2000) Therapeutic immunoadsorption increases the level of circulating soluble HLA molecules. Vox Sang, 78, 119-121.

Pfeiffer, K. A., Rebmann, V., Pässler, M., van der Ven, K., van der Ven, H., Krebs, D. and Grosse-Wilde, H. (2000) Soluble HLA levels in early pregnancy after in vitro fertilization. Hum Immunol, 61, 559-564.

Elsner, H. A., Pastucha, L. T., Rebmann, V., Grosse-Wilde, H. and Blasczyk, R. (2000) Identification of the novel allele HLA-A*6813 in two members of a family of Syrian origin: implications for bone marrow transplantation. Tissue Antigens, 55, 262-265.

Desai, S. A., Wang, X., Noronha, E. J., Zhou, Q., Rebmann, V., Grosse-Wilde, H., Moy, F. J., Powers, R. and Ferrone, S. (2000) Structural relatedness of distinct determinants recognized by monoclonal antibody TP25.99 on beta 2-microglobulin-associated and beta 2-microglobulin-free HLA class I heavy chains. J Immunol, 165, 3275-3283.


Rebmann, V., Pfeiffer, K., Pässler, M., Ferrone, S., Maier, S., Weiss, E. and Grosse-Wilde, H. (1999) Detection of soluble HLA-G molecules in plasma and amniotic fluid. Tissue Antigens, 53, 14-22.

Rebmann, V., Pässler, M., Erhard, J., Lange, R., Eigler, F. W. and Grosse-Wilde, H. (1999) Monitoring of soluble HLA class I size variants after liver transplantation. Hum Immunol, 60, 424-429.

Ditschkowski, M., Kreuzfelder, E., Rebmann, V., Ferencik, S., Majetschak, M., Schmid, E. N., Obertacke, U., Hirche, H., Schade, U. F. and Grosse-Wilde, H. (1999) HLA-DR expression and soluble HLA-DR levels in septic patients after trauma. Ann Surg, 229, 246-254.


Rebmann, V.
, Dornmair, K. and Grosse-Wilde, H. (1997) Biochemical analysis of plasma-soluble invariant chains and their complex formation with soluble HLA-DR. Tissue Antigens, 49, 438-442.


Blasczyk, R., Wehling, J., Onaldi-Mohr, D., Rebmann, V., Chandanayingyong, D. and Grosse-Wilde, H. (1996) Structural definition of the A*74 group: implications for matching in bone marrow transplantation with alternative donors. Tissue Antigens, 48, 205-209.


Rebmann, V., Kubens, B. S., Ferencik, S. and Grosse-Wilde, H. (1995) Biochemical analysis of HLA-DP gene products by isoelectric focusing and comparison with cellular and molecular genetic typing results. Exp Clin Immunogenet, 12, 36-47.


Rebmann, V., Doxiadis, I., Kubens, B. S. and Grosse-Wilde, H. (1992) Quantitation of the human component C4: definition of C4 Q0 alleles and C4A duplications. Vox Sang, 62, 117-123.


Doxiadis, G., Rebmann, V., Doxiadis, I., Krumbacher, K., Vriesendorp, H. M. and Grosse-Wilde, H. (1985) Polymorphism of the fourth complement component in the dog. Immunobiology, 169, 563-569.


Nückel, H., Castelli, E.C., Moreau, P., Ochsenfarth, C., Rebmann, V. (2012): Simple Methods for the Detection of HLA-G Variants in Coding and Non-Coding Regions. In Frank T. Christianson, MD and Brian D. Tait (Eds.): Methods in Molecular Biology series title: Immunogenetics: Methods and protocols Humana Press. USA. in press

Rebmann, V., Grosse-Wilde, H. (2010): Tumour-specific and tumour-associated antigens. In:Stavrou DK, Hagel C (Eds.): Immune Biology of Brain Tumours, Dustri-Verlag Dr. Karl Feistle, Munich – Orlando, 7 -21.

Rebmann, V., Grosse-Wilde, H. (2010): Immunological mechanisms of tumour cell destruction. In:Stavrou DK, Hagel C (Eds.): Immune Biology of Brain Tumours, Dustri-Verlag Dr. Karl Feistle, Munich – Orlando, 23 - 31.

Rebmann, V., Nückel, H. (2008) Die HLA-G Expression auf chronisch-lymphatischen Leukämiezellen ist mit einem ungünstigeren Krankheitsverlauf sowie einem immunsupprimierten Status der Patienten assoziiert. In: Westdeutsche Tumorzentrum Essen e.V. Jahrbuch 2006/2007: 104-107.

Rebmann, V., Grosse-Wilde, H. (2006): HLA-G Regulator der humanen Immunantwort Immuntransfer durch Transplantation. In: Rektorat der Universität Duisburg-Essen (Ed.): Essener Unikate, Berichte aus Forschung und Lehre, Medizin: Immunologie. Das Immunsystem – Freund oder Feind?, Wissenschaftsverlag FET & V, 27: 90 - 99.

Campoli, M., Cheney, R., Rebmann V, Worsham, M., Cabrera, T., Garridi, F., Tait, B., Ferrone, S. (2006): HLA antigen changes and cancer: A report from the 13th International Histocompatibility Workshop. In: JA Hanson (Ed.): Immunobiology of human MHC. Proceedings of the 13th International Histocompatibility Workshop and Conference. Hansen J., IHWG Press, Seattle, Washington , 1: 833-846.

Rebmann, V., Grosse-Wilde, H. (2000): Detection of soluble HLA. In JL Bidwell, C Navarrete (Eds): Histocompatibility Testing, Imperial College Press: 99-123.

Rebmann, V., Päßler, M., Erhardt, J., Eigler, F.W., Grosse-Wilde, H. (1997): Monitoring of soluble HLA class I molecular weight variants and allotypes after liver transplantation. In: D. Charon (Ed.): Genetic diversity of HLA - Functional and medical implication. Sevres, EDK International Publisher, 2: 548-550.

Thomsen, M., Christiansen, F., D'Alfonso, S., Dawkins, R., Delaney, N., Ferencik, S., Foissac, A,, Gonzalez-Escribano, M.F., Holdsworth, R., Ikaheimo, I., Klitz, W., Alcalay, D., Lindemann, M., Martinetti, M., Moghaddam, P.H., Moine, A., Moraes, M.E., Moraes, JR., Rebmann, V., Sevin, A., Siren, M.K., Schmeckpeper, B., Barmada, M., Borelli, I., Breda-Coimbra, H., Cambon-Thomsen, A., Carpenter, C.B., Carrington, M. and Chiewsilp, P. (1997): MHC recombinant families. In: D. Charron (Ed.): Genetic diversity of HLA – Functional and medical implication. Sevres, EDK International Publishers, 1: 188-197.